drugset / Trial / NCT06522360
Brigatinib Plus Chemotherapy or Local Consolidation Therapy in ALK Positive Advanced Non-small Cell Lung Cancer (BrightStar-2)
RandomizedSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to learn if the combination of brigatinib and either local consolidation therapy (such as radiotherapy or surgery) or chemotherapy (pemetrexed and carboplatin) can help to control the disease compared with brigatinib alone. The safety of these combinations will also be studied.
Timeline
- Start
- 2024-12-11
- Primary completion
- 2025-04-17
- Completion
- 2025-04-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Brigatinib | Small molecule | — | Oral |
| Subject | Carboplatin | Small molecule | — | Intravenous |
| Subject | Pemetrexed | Small molecule | — | Intravenous |